Microsoft word - caschma_huffakerdavid_071016_8604_t1.doc
Summary of rEEG Findings
Section 1: Overall Abnormality
Section 2: Drug Class Correlations
Correlations are based on a subset of more than 1,600 patients in the rEEG database having (1) similar rEEG features to this patient and (2) a change of two or more improvement in their Clinical Global Improvement Index (CGI).
Section 3: Individual Medication Responsivity
Subgroup ratings (S, I & R) are based on comparison to other subgroups within the overall medication group. Within the subgroup individual medications ratings (1, 2, 3) are relative to other medications in the subgroup only. When there is only one medication in a subgroup only the subgroup rating appears. Specific medication combinations may be incompatible.
Beta Blockers (Intermediate)
Key to symbols: S = sensitive, patients with similar neurophysiology were most often responsive to medications with this designation. R = resistant, patients with similar neurophysiology were least often responsive to medications with this designation. I = intermediate, patients with similar neurophysiology were neither consistently sensitive or consistently resistant to medications with this designation ND = No data in the database to support recommendations 1,2,3 = relative rankings amongst agents in a subgroup where 1 is highest and 3 is lowest.
The recording is certified by a trained EEG Technician to conform with CNS Response recording instructions that are established in
accordance with the American Clinical Neurophysiology Society guidelines.
This is a 21-channel, routine EEG (95816) recording of fair technical quality. Muscle and eye-blink artifacts were minimal during the
Alpha rhythm 10-11 Hz, with amplitudes ranging from 10-30 uV. There is 18-22 Hz activity of 0-30 uV amplitude in anterior leads.
Intermittent 3-5 Hz activity of semi-rhythmic character, having amplitudes of 30-50 uV, arises in the left temporal region.
INTERPRETATION: This patient's EEG shows a focus of intermittent slow activity in the left temporal region, suggesting the presence
of lesion of unspecified character in this area.
Meyer L.Proler, MD
Diplomate, ABCN in Evoked Potentials and Electroencephalography
Certified by ABEN with special competence in Quantified EEG Warning
Absolutely no consideration is given to medical appropriateness of any combination of medications. Ratings are specific to each agent; no combinatorial
ratings are given or implied. Nothing in this analysis is meant to suggest medication strategy without full consideration of all clinical factors, package insert
medication information, FDA approved usage and warnings, limitations on use of any agents for patients of any age, pregnancy status, or otherwise, cross
toxicities with other medications (psychotropic or otherwise), or any other relevant medical factor reasonably considered by a physician skilled and
experienced with patients diagnosed with behavioral disorders and the medications listed. This analysis is based upon segregated reporting of patients having
successfully reported outcomes of a change of 2 or more in the Clinical Global Improvement Index as reported by their physician and as correlated to
neurophysiological factors recorded on FDA approved Quantitative Electroencephalography Equipment and FDA approved software discriminating these
factors and stored in the Referenced-EEG database. Analysis is not segregated or correlated by diagnostic nomenclature. CNS Response does not monitor the
capability of EEG equipment suppliers, the regulatory status of the equipment or the condition and performance of equipment at the time of data collection.
Readers of this report should have read and understood the material in the CNS Response, Inc Physician's Information Binder. CNS Response, Inc will
facilitate physician consultancy for further interpretation and medical consideration when available.
Physicians considering the use of Beta-Blockers must be aware that they have not been approved by the FDA for treatment of certain behavioral disorders.
Beta-Blockers have been demonstrated in some studies to change neurophysiologic parameters in a way similar to some anticonvulsants and anxiolytics. Other
studies have reported their use in anxiety management. Use of a beta-blocker requires baseline & follow-up monitoring of resting pulse rate and blood
Ratings for Monoamine Oxidase Inhibitors (MAOI's) are shown as a subclass and individually in stimulant tables though the FDA may have approved
indications of these medications for some affective disorders. This classification reflects some similarity of the neurophysiological effect shown by these
agents and other stimulants. No other implications are intended. For further explanation see the CNSR Physician's Information Binder and/or consider
discussing this with the CNS Response Medical Director. The physician should be aware of the contraindications of using MAOI's with some medications.
NORONHA ET AL. : LEPTINOTARSA DECEMLINEATA SUSCEPTIBILITY TO INSECTICIDES Differential susceptibility to insecticides by Leptinotarsa decemlineata [Coleoptera: Chrysomelidae] populations from western Canada Christine Noronha1,2, Grant M. Duke1, Jason M. Chinn1,and Mark S. Goettel1,3 PHYTOPROTECTION 82 : 113-121 The susceptibility of Colorado potato beetles (Leptinotarsa decemlineata)(CPB) fr
Global Sun Partners L.P. (a.k.a Arava Power) Company Obtains $1,100,000 in Partnership Interests in Global Sun Partners New York, Tel Aviv August 2009- Global Sun Partners, also known as Arava Power (The “Company”), an Israeli based company located in Southern Israel, recently closed on a Series A round of financing comprised of partnership units. “We, as well as our